Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; do
Related stories
FDA Declines to Approve Summit Lung Cancer Drug After Trial Misses Survival Goal
The FDA declined to approve Summit Therapeutics' lung cancer drug after its trial missed a key survival goal.
M impact | REGULATION | Nov 15, 2026, 01:20 PM UTC
US Judge Again Blocks Trump Plan to Renovate DC Golf Course
A US judge temporarily blocked the plan, according to the headline and available report text.
L impact | REGULATION | Nov 15, 2026, 02:35 AM UTC
UK to Expand Jobs Guarantee Scheme for Young People
The British government will expand its jobs guarantee scheme for young people.
L impact | REGULATION | Nov 14, 2026, 10:30 PM UTC
Italy Fines Meta $887 Million Over Use of Android Gallery Media
Italy announced an €805 million ($887 million) fine against Meta over its use of photos and videos from Android galleries on Facebook.
M impact | REGULATION | Nov 14, 2026, 05:53 PM UTC
Italy Fines Meta €805 Million Over Android Data Access
Italy’s privacy regulator fined Meta Platforms Ireland €805 million, finding it accessed photos, videos and related information stored on Android devices without specific user perm
M impact | REGULATION | Nov 14, 2026, 03:10 PM UTC
Meta fined €805 million in Italy
Meta must pay a €805 million fine in Italy, Reuters reports.
M impact | REGULATION | Nov 14, 2026, 02:44 PM UTC